[go: up one dir, main page]

JP2005532369A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532369A5
JP2005532369A5 JP2004513288A JP2004513288A JP2005532369A5 JP 2005532369 A5 JP2005532369 A5 JP 2005532369A5 JP 2004513288 A JP2004513288 A JP 2004513288A JP 2004513288 A JP2004513288 A JP 2004513288A JP 2005532369 A5 JP2005532369 A5 JP 2005532369A5
Authority
JP
Japan
Prior art keywords
group
moiety
formula
ring
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004513288A
Other languages
Japanese (ja)
Other versions
JP4502804B2 (en
JP2005532369A (en
Filing date
Publication date
Priority claimed from HU0202001A external-priority patent/HUP0202001A2/en
Application filed filed Critical
Publication of JP2005532369A publication Critical patent/JP2005532369A/en
Publication of JP2005532369A5 publication Critical patent/JP2005532369A5/ja
Application granted granted Critical
Publication of JP4502804B2 publication Critical patent/JP4502804B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (20)

一般式（Ｉ）
Figure 2005532369
 ［式中、Ｒは、
・ 窒素含有単環式又は二環式芳香族部分（ここで、該芳香族部分は、１つ又は２つの芳香環（好ましくは、ピリジル環、ピリダジニル環、ピリミジニル環、ピラジニル環、イミダゾリル環、ピラゾリル環、チアゾリル環、イソチアゾリル環、オキサゾリル環、イソオキサゾリル環、オキサジアゾリル環、キノリニル環、イソキノリニル環、シンノリニル環、フタラジニル環、キナゾリニル環、キノキサリニル環、ベンゾイミダゾリル環、インダゾリル環、ベンゾチアゾリル環、ベンゾイソチアゾリル環、ベンゾオキサゾリル環又はベンゾイソオキサゾリル環）からなり、該環は、所与の場合において、互いに独立して、以下の基の１つ又は２つにより一置換又は二置換されている：Ｃ１−４アルキル基、Ｃ１−４アルコキシ基、ハロゲン原子、トリハロゲノメチル基、メチルチオ基、ニトロ基、シアノ基、Ｃ２−５アルコキシカルボニル基又はカルボキサミド基）を意味するか；
又は、
・ ｐ−トリルスルホニル基を意味するか；
又は、
・ Ｒ１ａ−ＣＨ２基（ここで、Ｒ１ａの意味は、水素、Ｃ１−４アルキル基、フェニル部分、ベンジル部分、フェニルエチル部分、フェニルエテニル部分、ナフチル部分、ピリジル部分、キノリル部分、イソキノリル部分、シンノリニル部分、フタラジニル部分、キナゾリニル部分、キノキサリニル部分、チエニル部分、フリル部分又はｐ−トリルスルホニル部分であり、これらは、所与の場合において、互いに独立して、１つ以上のＣ１−４アルキル基、Ｃ１−４アルコキシ基、アルキレンジオキシ基、ハロゲン原子、トリハロゲノメチル基、ニトロ基又はシアノ基で置換されている）を意味するか；
又は、
・ Ｒ１ｂ−ＣＯ基（ここで、Ｒ１ｂの意味は、Ｃ１−４アルキル基、フェニル部分、ベンジル部分、フェニルエチル部分、フェニルエテニル部分、ナフチル部分、ピリジル部分、キノリル部分、イソキノリル部分、シンノリニル部分、フタラジニル部分、キナゾリニル部分又はキノキサリニル部分（これらは、場合により、互いに独立して、１つ以上のＣ１−４アルキル基、Ｃ１−４アルコキシ基、アルキレンジオキシ基、ハロゲン原子、トリハロゲノメチル基、ニトロ基又はシアノ基で置換されている）であるか；一置換若しくは二置換されているアミノ基、Ｎ含有飽和ヘテロ環部分（好ましくは、ピロリジノ環、ピペリジノ環、ピペラジノ環若しくはモルホリノ環を含有する基である））を意味し；
Ｂは、式（１）
Figure 2005532369
 式（２）
Figure 2005532369
 式（３）
Figure 2005532369
 又は式（４）
Figure 2005532369
 で表される基を意味し；
Ｚは、式（Ａ）
Figure 2005532369
 式（Ｂ）
Figure 2005532369
 式（Ｃ）
Figure 2005532369
 式（Ｄ）
Figure 2005532369
 式（Ｅ）
Figure 2005532369
 又は式（Ｆ）
Figure 2005532369
 の基を意味する］
で表される化合物、及び、その塩、異性体、互変異性体、水和物又は溶媒和物。 Formula (I)
Figure 2005532369
 [Wherein R is
A nitrogen-containing monocyclic or bicyclic aromatic moiety, wherein the aromatic moiety is one or two aromatic rings (preferably pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl Ring, thiazolyl ring, isothiazolyl ring, oxazolyl ring, isoxazolyl ring, oxadiazolyl ring, quinolinyl ring, isoquinolinyl ring, cinnolinyl ring, phthalazinyl ring, quinazolinyl ring, quinoxalinyl ring, benzoimidazolyl ring, indazolyl ring, benzoisoazolyl ring, benzoisothiazolyl ring, Benzoxazolyl ring or benzoisoxazolyl ring), which in a given case, independently of one another, are mono- or disubstituted by one or two of the following groups: C 1-4 alkyl group, C 1-4 alkoxy groups, halogen atoms , Trihalogenomethyl group, methylthio group, nitro, cyano, or means a C 2-5 alkoxycarbonyl group or carboxamido group);
Or
Means a p-tolylsulfonyl group;
Or
R 1a —CH 2 group (where R 1a means hydrogen, C 1-4 alkyl group, phenyl moiety, benzyl moiety, phenylethyl moiety, phenylethenyl moiety, naphthyl moiety, pyridyl moiety, quinolyl moiety, An isoquinolyl moiety, a cinnolinyl moiety, a phthalazinyl moiety, a quinazolinyl moiety, a quinoxalinyl moiety, a thienyl moiety, a furyl moiety or a p-tolylsulfonyl moiety, which, in a given case, independently of one another, one or more C 1- 4 alkyl group, C 1-4 alkoxy group, alkylenedioxy group, halogen atom, trihalogenomethyl group, nitro group or cyano group).
Or
R 1b —CO group (where R 1b means C 1-4 alkyl group, phenyl moiety, benzyl moiety, phenylethyl moiety, phenylethenyl moiety, naphthyl moiety, pyridyl moiety, quinolyl moiety, isoquinolyl moiety, A cinnolinyl moiety, a phthalazinyl moiety, a quinazolinyl moiety or a quinoxalinyl moiety (which are optionally, independently of one another, one or more C 1-4 alkyl groups, C 1-4 alkoxy groups, alkylenedioxy groups, halogen atoms, A substituted or unsubstituted amino group, an N-containing saturated heterocyclic moiety (preferably a pyrrolidino ring, piperidino ring, piperazino ring or morpholino). Means a group containing a ring));
B is the formula (1)
Figure 2005532369
 Formula (2)
Figure 2005532369
 Formula (3)
Figure 2005532369
 Or formula (4)
Figure 2005532369
 Means a group represented by:
Z is the formula (A)
Figure 2005532369
 Formula (B)
Figure 2005532369
 Formula (C)
Figure 2005532369
 Formula (D)
Figure 2005532369
 Formula (E)
Figure 2005532369
 Or formula (F)
Figure 2005532369
 Means the group]
And a salt, isomer, tautomer, hydrate or solvate thereof. Ｒが、
・ 窒素含有単環式又は二環式芳香族部分（ここで、該芳香族部分は、１つ又は２つの芳香環（好ましくは、ピリジル環、ピリダジニル環、ピリミジニル環、ピラジニル環、イミダゾリル環、ピラゾリル環、チアゾリル環、イソチアゾリル環、オキサゾリル環、イソオキサゾリル環、オキサジアゾリル環、キノリニル環、イソキノリニル環、シンノリニル環、フタラジニル環、キナゾリニル環、キノキサリニル環、ベンゾイミダゾリル環、インダゾリル環、ベンゾチアゾリル環、ベンゾイソチアゾリル環、ベンゾオキサゾリル環又はベンゾイソオキサゾリル環）からなり、該環は、所与の場合において、互いに独立して、以下の基の１つ又は２つにより一置換又は二置換されている：Ｃ１−４アルキル基、Ｃ１−４アルコキシ基、ハロゲン原子、トリハロゲノメチル基、メチルチオ基、ニトロ基、シアノ基）を意味するか；
又は、
・ ｐ−トリルスルホニル基を意味するか；
又は、
・ Ｒ１ａ−ＣＨ２基（ここで、Ｒ１ａの意味は、水素、Ｃ１−４ アルキル基、フェニル部分、ベンジル部分、フェニルエチル部分、フェニルエテニル部分、ナフチル部分、ピリジル部分、キノリル部分、イソキノリル部分、シンノリニル部分、フタラジニル部分、キナゾリニル部分、キノキサリニル部分、チエニル部分、フリル部分又はｐ−トリルスルホニル部分であり、これらは、所与の場合において、互いに独立して、１つ以上のＣ１−４アルキル基、Ｃ１−４アルコキシ基、アルキレンジオキシ基、ハロゲン原子、トリハロゲノメチル基、ニトロ基又はシアノ基で置換されている）を意味するか；又は、
・ Ｒ１ｂ−ＣＯ基（ここで、Ｒ１ｂの意味は、Ｃ１−４アルキル基、フェニル部分、ベンジル部分、フェニルエチル部分、フェニルエテニル部分、ナフチル部分、ピリジル部分、キノリル部分、イソキノリル部分、シンノリニル部分、フタラジニル部分、キナゾリニル部分又はキノキサリニル部分（これらは、場合により、互いに独立して、１つ以上のＣ１−４アルキル基、Ｃ１−４アルコキシ基、アルキレンジオキシ基、ハロゲン原子、トリハロゲノメチル基、ニトロ基又はシアノ基で置換されている）であるか；一置換若しくは二置換されているアミノ基、Ｎ含有飽和ヘテロ環部分（好ましくは、ピロリジノ環、ピペリジノ環、ピペラジノ環若しくはモルホリノ環を含有する基である））を意味し；
Ｂが、式（１）、式（２）、式（３）又は式（４）で表される基を意味し；
Ｚが、式（Ａ）、式（Ｂ）、式（Ｃ）、式（Ｄ）、式（Ｅ）又は式（Ｆ）の基を意味する；
請求項１で定義されている一般式（Ｉ）の化合物、及び、その塩、異性体、互変異性体、水和物又は溶媒和物。 R is
A nitrogen-containing monocyclic or bicyclic aromatic moiety, wherein the aromatic moiety is one or two aromatic rings (preferably pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl Ring, thiazolyl ring, isothiazolyl ring, oxazolyl ring, isoxazolyl ring, oxadiazolyl ring, quinolinyl ring, isoquinolinyl ring, cinnolinyl ring, phthalazinyl ring, quinazolinyl ring, quinoxalinyl ring, benzoimidazolyl ring, indazolyl ring, benzoisoazolyl ring, benzoisothiazolyl ring, Benzoxazolyl ring or benzoisoxazolyl ring), which in a given case, independently of one another, are mono- or disubstituted by one or two of the following groups: C 1-4 alkyl group, C 1-4 alkoxy groups, halogen atoms , Trihalogenomethyl group, methylthio group, nitro group, or means a cyano group);
Or
Means a p-tolylsulfonyl group;
Or
R 1a —CH 2 group (where R 1a means hydrogen, C 1-4 alkyl group, phenyl moiety, benzyl moiety, phenylethyl moiety, phenylethenyl moiety, naphthyl moiety, pyridyl moiety, quinolyl moiety, An isoquinolyl moiety, a cinnolinyl moiety, a phthalazinyl moiety, a quinazolinyl moiety, a quinoxalinyl moiety, a thienyl moiety, a furyl moiety or a p-tolylsulfonyl moiety, which, in a given case, independently of one another, one or more C 1- 4 alkyl group, C 1-4 alkoxy group, alkylenedioxy group, halogen atom, trihalogenomethyl group, nitro group or cyano group); or
R 1b —CO group (where R 1b means C 1-4 alkyl group, phenyl moiety, benzyl moiety, phenylethyl moiety, phenylethenyl moiety, naphthyl moiety, pyridyl moiety, quinolyl moiety, isoquinolyl moiety, A cinnolinyl moiety, a phthalazinyl moiety, a quinazolinyl moiety or a quinoxalinyl moiety (which are optionally, independently of one another, one or more C 1-4 alkyl groups, C 1-4 alkoxy groups, alkylenedioxy groups, halogen atoms, A substituted or unsubstituted amino group, an N-containing saturated heterocyclic moiety (preferably a pyrrolidino ring, piperidino ring, piperazino ring or morpholino). Means a group containing a ring));
B represents a group represented by formula (1), formula (2), formula (3) or formula (4);
Z represents a group of formula (A), formula (B), formula (C), formula (D), formula (E) or formula (F);
A compound of general formula (I) as defined in claim 1 and salts, isomers, tautomers, hydrates or solvates thereof. Ｒが、
・ ピリミジニル基、ピリジニル基、ピラジニル基、ピリダジニル基、ベンゾチアゾリル基、ベンゾイソチアゾリル基、ベンゾオキサゾリル基又はベンゾイソオキサゾリル基（これらは、所与の場合において、互いに独立して、以下の基の１つ又は２つににより一置換又は二置換されている：Ｃ１−４アルキル基、Ｃ１−４アルコキシ基、ハロゲン原子、ニトロ基、シアノ基、Ｃ２−５アルコキシカルボニル基又はカルボキサミド基）を意味するか；
又は、
・ ｐ−トリルスルホニル基を意味するか；
又は、
・ Ｒ１ａ−ＣＨ２基（ここで、Ｒ１ａの意味は、ベンジル基又はフェニルエテニル基であり、その際、該基は、所与の場合において、独立して、１つ以上のＣ１−４アルキル基又はアルキレンジオキシ基で置換されている）を意味するか；
又は、
・ Ｒ１ｂＣＯ基（ここで、Ｒ１ｂの意味は、フェニル基、ベンジル基、フェニルエチル基、フェニルエテニル基又はピペリジノ基であり、その際、該基は、所与の場合において、互いに独立して、アルキレンジオキシ基で置換されている）を意味し；
Ｂが、式（１）、式（２）、式（３）又は式（４）の基を意味し；
Ｚが、式（Ａ）又は式（Ｂ）の基を意味する；
請求項１で定義されている一般式（Ｉ）の化合物、及び、その塩、異性体、互変異性体、水和物又は溶媒和物。 R is
A pyrimidinyl group, a pyridinyl group, a pyrazinyl group, a pyridazinyl group, a benzothiazolyl group, a benzoisothiazolyl group, a benzoxazolyl group, or a benzoisoxazolyl group, Is mono- or disubstituted by one or two of the following groups: C 1-4 alkyl group, C 1-4 alkoxy group, halogen atom, nitro group, cyano group, C 2-5 alkoxycarbonyl group or Carboxamide group);
Or
Means a p-tolylsulfonyl group;
Or
An R 1a —CH 2 group, wherein R 1a is a benzyl group or a phenylethenyl group, wherein the group independently represents, in a given case, one or more C 1 -4 alkyl group or alkylenedioxy group or means) has been replaced;
Or
A R 1b CO group (where R 1b means a phenyl group, a benzyl group, a phenylethyl group, a phenylethenyl group or a piperidino group, in which the groups are independent of each other in a given case) Substituted with an alkylenedioxy group);
B represents a group of formula (1), formula (2), formula (3) or formula (4);
Z represents a group of formula (A) or formula (B);
A compound of general formula (I) as defined in claim 1 and salts, isomers, tautomers, hydrates or solvates thereof. Ｒが、
・ ピリミジニル基、ピリジニル基、ピラジニル基、ピリダジニル基、ベンゾチアゾリル基、ベンゾイソチアゾリル基、ベンゾオキサゾリル基又はベンゾイソオキサゾリル基（これらは、所与の場合において、互いに独立して、以下の基の１つ又は２つににより一置換又は二置換されている：Ｃ１−４アルキル基、Ｃ１−４アルコキシ基、ハロゲン原子、ニトロ基又はシアノ基）を意味するか；
又は、
・ ｐ−トリルスルホニル基を意味するか；
又は、
・ Ｒ１ａ−ＣＨ２基（ここで、Ｒ１ａの意味は、ベンジル基又はフェニルエテニル基であり、その際、該基は、所与の場合において、独立して、１つ以上のＣ１−４アルキル基又はアルキレンジオキシ基で置換されている）を意味するか；
又は、
・ Ｒ１ｂＣＯ基（ここで、Ｒ１ｂの意味は、フェニル基、ベンジル基、フェニルエチル基、フェニルエテニル基又はピペリジノ基であり、その際、該基は、所与の場合において、互いに独立して、アルキレンジオキシ基で置換されている）を意味し；
Ｂが、式（１）、式（２）、式（３）又は式（４）の基を意味し；
Ｚが、式（Ａ）又は式（Ｂ）の基を意味する；
請求項１で定義されている一般式（Ｉ）の化合物、及び、その塩、異性体、互変異性体、水和物又は溶媒和物。 R is
A pyrimidinyl group, a pyridinyl group, a pyrazinyl group, a pyridazinyl group, a benzothiazolyl group, a benzoisothiazolyl group, a benzoxazolyl group, or a benzoisoxazolyl group, Or a mono- or di-substituted by one or two of the groups: a C 1-4 alkyl group, a C 1-4 alkoxy group, a halogen atom, a nitro group or a cyano group);
Or
Means a p-tolylsulfonyl group;
Or
An R 1a —CH 2 group, wherein R 1a is a benzyl group or a phenylethenyl group, wherein the group independently represents, in a given case, one or more C 1 -4 alkyl group or alkylenedioxy group or means) has been replaced;
Or
A R 1b CO group (where R 1b means a phenyl group, a benzyl group, a phenylethyl group, a phenylethenyl group or a piperidino group, in which the groups are independent of each other in a given case) Substituted with an alkylenedioxy group);
B represents a group of formula (1), formula (2), formula (3) or formula (4);
Z represents a group of formula (A) or formula (B);
A compound of general formula (I) as defined in claim 1 and salts, isomers, tautomers, hydrates or solvates thereof. Ｒが、ニトロ基又はシアノ基で置換されているピリミジル基、ピリジル基又はピラジニル基を意味し、Ｂが、式（１）又は式（２）の基を意味し、Ｚが、式（Ａ）又は式（Ｂ）の基を意味する、請求項１で定義されている一般式（Ｉ）の化合物、及び、その塩、異性体、互変異性体、水和物又は溶媒和物。   R represents a pyrimidyl group, pyridyl group or pyrazinyl group substituted with a nitro group or a cyano group, B represents a group of the formula (1) or formula (2), and Z represents a formula (A) Or a compound of general formula (I) as defined in claim 1 and a salt, isomer, tautomer, hydrate or solvate thereof, which means a group of formula (B). （４Ｒ）−３−（２−｛［８−（２−ピリミジニル）−８−アザビシクロ［３．２．１］オクト−３−イル］エキソ−アミノ｝アセチル）チアゾリジン−４−カルボニトリル。   (4R) -3- (2-{[8- (2-pyrimidinyl) -8-azabicyclo [3.2.1] oct-3-yl] exo-amino} acetyl) thiazolidine-4-carbonitrile. （４Ｒ）−３−（２−｛［８−（５−シアノピリジン−２−イル）−８−アザビシクロ［３．２．１］オクタン−３−イル］−エキソ−アミノ｝アセチル）チアゾリジン−４−カルボニトリル。   (4R) -3- (2-{[8- (5-Cyanopyridin-2-yl) -8-azabicyclo [3.2.1] octane-3-yl] -exo-amino} acetyl) thiazolidine-4 -Carbonitrile. （４Ｒ）−３−（２−｛［８−（５−シアノピリジン−２−イル）−８−アザビシクロ［３．２．１］オクタン−３−イル］−エンド−アミノ｝アセチル）チアゾリジン−４−カルボニトリル。   (4R) -3- (2-{[8- (5-Cyanopyridin-2-yl) -8-azabicyclo [3.2.1] octane-3-yl] -endo-amino} acetyl) thiazolidine-4 -Carbonitrile. （４Ｒ）−３−（２−｛［８−（２−ピラジニル）−８−アザビシクロ［３．２．１］オクタン−３−イル］−エキソ−アミノ｝アセチル）チアゾリジン−４−カルボニトリル。   (4R) -3- (2-{[8- (2-Pyrazinyl) -8-azabicyclo [3.2.1] octane-3-yl] -exo-amino} acetyl) thiazolidine-4-carbonitrile. （２Ｓ）−１−（２−｛［８−（５−ニトロピリジン−２−イル）−８−アザビシクロ［３．２．１］オクタン−３−イル］−エキソ−アミノ｝アセチル）ピロリジン−２−カルボニトリル。   (2S) -1- (2-{[8- (5-Nitropyridin-2-yl) -8-azabicyclo [3.2.1] octane-3-yl] -exo-amino} acetyl) pyrrolidine-2 -Carbonitrile. 遊離化合物の形態又は塩の形態にある一般式（Ｉ）
Figure 2005532369
 ［式中、Ｒ、Ｂ及びＺの意味は、請求項１で定義されているものと同じである］の化合物又はその異性体若しくは溶媒和物、及び、少なくとも１種の製薬上許容される担体又は希釈剤を含んでいることを特徴とする、医薬組成物。 General formula (I) in the form of a free compound or in the form of a salt
Figure 2005532369
 Wherein R, B and Z have the same meaning as defined in claim 1, or an isomer or solvate thereof, and at least one pharmaceutically acceptable carrier. Or the pharmaceutical composition characterized by including the diluent. 一般式（Ｉ）
Figure 2005532369
 ［式中、Ｒ、Ｂ及びＺの意味は、請求項１で定義されているものと同じである］の化合物を調製する方法であって、一般式（ＩＩ）
Figure 2005532369
 ［式中、Ｒの意味は、上記で定義されているとおりである］の化合物を一般式（ＩＩＩ）
Figure 2005532369
 ［式中、Ｚの意味は、上記で定義されているとおりである］の化合物と反応させ、生じた一般式（Ｉ）の化合物又はその塩を反応混合物から単離することを特徴とする、前記方法。 Formula (I)
Figure 2005532369
 A process for preparing a compound of the general formula (II) wherein R, B and Z have the same meaning as defined in claim 1
Figure 2005532369
 [Wherein the meaning of R is as defined above] is represented by the general formula (III)
Figure 2005532369
 Reacting with a compound of the formula wherein Z is as defined above, and isolating the resulting compound of general formula (I) or a salt thereof from the reaction mixture, Said method. ＤＰＰ−ＩＶ酵素活性を阻害するのに適していることで、従って、ＤＰＰ−ＩＶ酵素濃度に関連する疾患を治療するのに適している医薬組成物を調製するための、一般式（Ｉ）
Figure 2005532369
 ［式中、Ｒ、Ｂ及びＺの意味は、請求項１で定義されているとおりである］で表される化合物の使用。 General formula (I) for preparing a pharmaceutical composition suitable for inhibiting DPP-IV enzyme activity and thus suitable for treating diseases associated with DPP-IV enzyme concentration
Figure 2005532369
 [Wherein the meanings of R, B and Z are as defined in claim 1]. ＤＰＰ−ＩＶ酵素を阻害する方法及びＤＰＰ−ＩＶ酵素濃度に関連する疾患を治療する方法であって、遊離化合物の形態又塩形態にある治療有効量の請求項１で定義されている一般式（Ｉ）
Figure 2005532369
 の化合物を適用することを特徴とする、前記方法。 A method for inhibiting a DPP-IV enzyme and a method for treating a disease associated with DPP-IV enzyme concentration, wherein the therapeutically effective amount is in the form of a free compound or in the salt form of the general formula (1) I)
Figure 2005532369
 Applying the compound of the above. 一般式（ＩＩ）
Figure 2005532369
 ［式中、Ｒ及びＢの意味は請求項１で定義されているとおりである］で表される化合物及びそれらの塩。 Formula (II)
Figure 2005532369
 [Wherein the meanings of R and B are as defined in claim 1] and salts thereof. 一般式（Ｖ）
Figure 2005532369
 ［式中、Ｒの意味は請求項１で定義されているとおりであり、Ｙはｔ−ブトキシカルボニル基を意味する］で表される化合物。 General formula (V)
Figure 2005532369
 [Wherein, the meaning of R is as defined in claim 1 and Y means a t-butoxycarbonyl group]. 一般式（ＶＩＩ）
Figure 2005532369
 ［式中、Ｚの意味は、請求項１で定義されているとおりである］で表される化合物。 Formula (VII)
Figure 2005532369
 [Wherein the meaning of Z is as defined in claim 1]. 一般式（ＶＩＩＩ）
Figure 2005532369
 ［式中、Ｚの意味は、請求項１で定義されているとおりである］で表される化合物及びそれらの塩。 Formula (VIII)
Figure 2005532369
 [Wherein the meaning of Z is as defined in claim 1] and salts thereof. 一般式（ＩＸ）
Figure 2005532369
 ［式中、Ｚの意味は、請求項１で定義されているとおりである］で表される化合物。 Formula (IX)
Figure 2005532369
 [Wherein the meaning of Z is as defined in claim 1]. 一般式（ＩＩＩ）
Figure 2005532369
 ［式中、Ｚの意味は、請求項１で定義されているとおりである］で表される化合物。 Formula (III)
Figure 2005532369
 [Wherein the meaning of Z is as defined in claim 1].
JP2004513288A 2002-06-14 2003-06-11 Azabicyclo-octane and nonane derivatives having DDP-IV inhibitory activity Expired - Fee Related JP4502804B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0202001A HUP0202001A2 (en) 2002-06-14 2002-06-14 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
PCT/HU2003/000041 WO2003106456A2 (en) 2002-06-14 2003-06-11 New compounds

Publications (3)

Publication Number Publication Date
JP2005532369A JP2005532369A (en) 2005-10-27
JP2005532369A5 true JP2005532369A5 (en) 2006-04-20
JP4502804B2 JP4502804B2 (en) 2010-07-14

Family

ID=90001551

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004513288A Expired - Fee Related JP4502804B2 (en) 2002-06-14 2003-06-11 Azabicyclo-octane and nonane derivatives having DDP-IV inhibitory activity

Country Status (21)

Country Link
US (2) US7781455B2 (en)
EP (1) EP1517907B1 (en)
JP (1) JP4502804B2 (en)
KR (1) KR100756761B1 (en)
CN (1) CN100347170C (en)
AT (1) ATE495162T1 (en)
AU (1) AU2003244880B2 (en)
BR (1) BR0311771A (en)
DE (1) DE60335717D1 (en)
EA (1) EA008166B1 (en)
HR (1) HRP20050027A2 (en)
HU (1) HUP0202001A2 (en)
IL (1) IL165434A0 (en)
IS (1) IS7638A (en)
MX (1) MXPA04012691A (en)
NO (1) NO20050199L (en)
NZ (1) NZ537633A (en)
PL (1) PL372799A1 (en)
RS (1) RS109104A (en)
WO (1) WO2003106456A2 (en)
ZA (1) ZA200409907B (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400321A2 (en) 2001-06-27 2004-08-30 Smithkline Beecham Corp. Fluoropyrrolidines as dipeptidyl peptidase inhibitors and pharmaceutical compositions containing them
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2519939A1 (en) * 2003-03-26 2004-10-14 Merck & Co., Inc. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
ZA200602051B (en) 2003-08-13 2007-10-31 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
NZ548440A (en) 2004-02-05 2009-07-31 Kyorin Seiyaku Kk Bicycloester derivative inhibitng DPP-IV for treatment of diabetes or similar
WO2005077900A1 (en) * 2004-02-18 2005-08-25 Kyorin Pharmaceutical Co., Ltd. Bicyclic amide derivatives
US7514571B2 (en) * 2004-02-27 2009-04-07 Kyorin Pharmaceutical Co., Ltd. Bicyclo derivative
EP1814551A2 (en) 2004-09-20 2007-08-08 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
KR20080000665A (en) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 Dipeptidyl Peptidase-IV Inhibitors
MX2007015216A (en) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors.
EP1917001A2 (en) * 2005-08-11 2008-05-07 F.Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
CA2618087A1 (en) * 2005-08-19 2007-03-01 Elan Pharmaceuticals, Inc. Bridged n-bicyclic sulfonamido inhibitors of gamma secretase
ZA200802857B (en) 2005-09-14 2009-09-30 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (en) 2005-09-16 2009-02-04 武田药品工业株式会社 Process for preparing pyrimidinedione derivatives
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
JP5101489B2 (en) * 2006-03-08 2012-12-19 杏林製薬株式会社 Process for producing aminoacetylpyrrolidinecarbonitrile derivative and its production intermediate
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
TW200811170A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
FR2902791B1 (en) * 2006-06-27 2008-08-22 Sanofi Aventis Sa DERIVATIVES OF TROPANE UREES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
PE20080212A1 (en) 2006-06-27 2008-04-25 Sanofi Aventis UREAS DERIVATIVES OF PIPERIDINE OR PYRROLIDINE AS MODULATORS OF 11B-HYDROXIESTEROID DEHYDROGENASE TYPE 1 (11BHSD1)
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
JPWO2008114857A1 (en) * 2007-03-22 2010-07-08 杏林製薬株式会社 Process for producing aminoacetylpyrrolidinecarbonitrile derivative
GB0713602D0 (en) * 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US8012956B2 (en) * 2007-10-25 2011-09-06 Exelixis, Inc. Tropane compounds
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2322499A4 (en) * 2008-08-07 2011-12-21 Kyorin Seiyaku Kk PROCESS FOR PRODUCING A BICYCLOÝ2.2.2¨OCTYLAMINE DERIVATIVE
CN102186474A (en) * 2008-08-14 2011-09-14 杏林制药株式会社 stable pharmaceutical composition
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
JP2013503135A (en) 2009-08-26 2013-01-31 サノフイ Novel crystalline heteroaromatic fluoroglycoside hydrate, pharmaceutical comprising the compound and use thereof
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683701B1 (en) 2011-03-08 2014-12-24 Sanofi Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
ES2805743T3 (en) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Method and pharmaceutical composition for use in the treatment of diabetes
JP2020515639A (en) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド PPARγ agonists for the treatment of progressive supranuclear palsy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5592384A (en) * 1978-12-30 1980-07-12 Beecham Group Ltd Compound having pharmacological activity
IL59004A0 (en) * 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CA2390231A1 (en) * 1999-11-12 2001-05-17 Paul Jackson Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
JP2003520849A (en) * 2000-01-24 2003-07-08 ノボ ノルディスク アクティーゼルスカブ N-substituted 2-cyanopyrroles and -pyrrolines which are inhibitors of the enzyme DPP-IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
DK1325910T3 (en) * 2000-10-06 2008-11-10 Mitsubishi Tanabe Pharma Corp Aliphatic nitrogen-containing five-membered ring compounds
ATE370943T1 (en) * 2001-06-27 2007-09-15 Smithkline Beecham Corp FLUOROPYRROLIDINE AS DIPEPTIDYL-PEPTIDASE INHIBITORS
HUP0200849A2 (en) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them

Similar Documents

Publication Publication Date Title
JP2005532369A5 (en)
US11028066B2 (en) Inhibitors of lysine specific demethylase-1
JP4502804B2 (en) Azabicyclo-octane and nonane derivatives having DDP-IV inhibitory activity
JP4559737B2 (en) N-aminoacetyl-pyrrolidine-2-carbonitrile and its use as a DDP-IV inhibitor
JP4853965B2 (en) Adamantane derivatives and azabicyclooctane derivatives and azabicyclononane derivatives and methods for their preparation and their use as DPP-IV inhibitors
JP4696069B2 (en) Derivatives of N- [heteroallyl (piperidin-2-yl) methyl] benzamide, process for its preparation and use in this therapy
US9199979B2 (en) Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
TWI344955B (en) Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
KR100360633B1 (en) 6-Phenylpyridyl-2-amine Derivatives Useful as NOS Inhibitors
US20070167435A1 (en) Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
WO2004052880A1 (en) Pyridine derivatives as jnk inhibitors and their use
MXPA05006917A (en) 4, 5-diarylthiazole derivatives as cb-1 ligands.
MXPA05006919A (en) 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators.
CA2444595A1 (en) Benzimidazolone derivatives
JPWO2000039116A1 (en) Aminopyrazole derivatives
WO2002102778A1 (en) Phenylpyridine carbonyl piperazine derivative
JP2006527770A (en) 2-Substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
MXPA06004279A (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors.
JPH05148228A (en) Novel 1,4-disubstituted piperidine, prepara- tion thereof and therapeutic application thereof
US5670522A (en) Dopamine receptor subtype ligands
FR2943669A1 (en) NICOTINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CA2743558A1 (en) Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof
CN101300226B (en) Alkylcarbamoyl naphthoxyoctenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and process for preparing the same
JPWO2000023436A1 (en) quinazolinone derivatives
WO2017018475A1 (en) Condensed pyrazole derivative having new linker site and medicinal use of same